SAB Biotherapeutics, Inc. (SABS)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Income (loss) from continuing operations before income taxes, noncontrolling interest | - | -10,349,410 | ||
| Research and development | 6,996,660 | 7,830,745 | ||
| General and administrative | 2,735,401 | 3,478,621 | ||
| Total operating expenses | 9,732,061 | 11,309,366 | ||
| Loss from operations | -9,732,061 | -11,309,366 | ||
| Other income | 295,630 | 754,647 | ||
| Interest income | 13,562 | 277,174 | ||
| Interest expense | 64,345 | 78,036 | ||
| Changes in fair value of warrant liabilities | 627,056 | -6,171 | ||
| Total other income (expense) | -382,209 | 959,956 | ||
| Net loss | -10,114,270 | -10,349,410 | ||
| Diluted earnings per common share | -1.09 | -1.12 | ||
| Net loss per share, basic | -1.09 | -1.12 | ||
| Weighted-average common shares outstanding - basic | 9,294,469 | 9,259,192 | ||
| Weighted-average common shares outstanding - diluted | 9,294,469 | 9,259,192 | ||